Warning: The NCBI web site requires JavaScript to function. more...
An official website of the United States government
The .gov means it's official. Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you're on a federal government site.
The site is secure. The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.
Antiviral activity against wild type Vaccinia virus IHD infected in monkey Vero cells assessed as reduction in plaque formation measured after 7 days
Assay data:1 Tested
Summary
Antiviral activity against Vaccinia virus IHD infected in African green monkey Vero cells assessed as reduction in plaque formation measured after 7 days
Antiviral activity against wild type Vaccinia virus infected in human HFF cells assessed as reduction in viral replication measured after 5 days by microscopic analysis
Assay data:1 Active, 1 Tested
Antiviral activity against Cowpox virus Brighton infected in human HFF cells assessed as reduction in viral replication measured after 3 days
Assay data:2 Tested
Antiviral activity against Vaccinia virus Copenhagen infected in human HFF cells assessed as reduction in viral replication measured after 3 days
Assay data:1 Active, 2 Tested
Antiviral activity against Vaccinia virus infected in human HFF cells assessed as reduction in plaque formation measured after 7 days by colorimetric assay
Antiviral activity against Vaccinia virus GFP infected in green monkey HT-1080 cells assessed as reduction in plaque formation measured after 2.5 days by microscopic analysis
Antiviral activity against Vaccinia virus GFP infected in green monkey CV-1 cells assessed as reduction in plaque formation measured after 2.5 days by microscopic analysis
Antiviral activity against Vaccinia virus WR-GFP infected in BSC40 cells assessed as reduction in plaque formation measured after 72 hrs by crystal violet staining based analysis
Antiviral activity against Vaccinia virus IHD-J infected in BSC40 cells assessed as reduction in plaque formation measured after 72 hrs by crystal violet staining based analysis
Assay data:4 Active, 2 Activity ≤ 1 µM, 4 Tested
Antiviral activity against Vaccinia virus VG9 infected in African green monkey BSC-1 cells
Assay data:10 Active, 3 Activity ≤ 1 µM, 10 Tested
Antiviral activity against Vaccinia virus infected in African green monkey BSC-1 cells
Antiviral activity against Vaccinia virus infected in African green monkey CV-1 cells assessed as reduction in virus-induced cytopathic effect incubated for 5 days by colorimetric analysis
Assay data:11 Active, 8 Activity ≤ 1 µM, 13 Tested
Antiviral activity against Vaccinia virus infected in African green monkey Vero cells incubated for 24 hrs
Antiviral activity against Vaccinia virus Copenhagen infected in human HFF cells assessed as assessed as reduction in virus-induced cytopathic effect incubated for 7 days by microscopic analysis
Assay data:5 Active, 6 Tested
Antiviral activity against Vaccinia virus infected in monkey BSC40 cells assessed as reduction in virus-induced cytopathic effect
Antiviral activity against Vaccinia virus infected in African green monkey BSC-1 cells incubated for 24 hrs by microscopic analysis
Antiviral activity against Vaccinia virus infected in human HEL cells
Assay data:9 Active, 4 Activity ≤ 1 µM, 9 Tested
Antiviral activity against Vaccinia virus infected in African green monkey Vero cells
Assay data:4 Active, 4 Tested
Antiviral activity against Vaccinia virus Copenhagen infected in African green monkey Vero cells
Assay data:1 Active, 1 Activity ≤ 1 µM, 2 Tested
Filters: Manage Filters
Your browsing activity is empty.
Activity recording is turned off.
Turn recording back on